Related Experiment Video
Updated: Aug 25, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Antifungal therapy for febrile neutropenia: issues in clinical trial design
1Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N D3-100, Seattle, WA 98119, USA. kmarr@fhcrc.org
Abstract:
Amphotericin B therapy for fever during neutropenia became a standard practice approximately 20 years ago. Treatment of febrile neutropenia has since become a common indication sought in the development of new antifungals, with several alternatives approved for 'empirical therapy' based on the results of randomized clinical trials. Recent studies have highlighted problematic issues in trial design and interpretation; inclusion criteria and the definition of success are two examples of controversial issues. Here, issues in trial design will be reviewed to address the question: Can (and should) new antifungals be evaluated for treatment of fever during neutropenia?
Related Concept Videos
Antifungal Agents
Cryptococcal Meningitis
Clinical Trials: Overview
